Targeting brain-metastatic breast tumors with HER3-homing bioparticles
While the median survival for patients with metastatic breast cancer is ~2-5 years depending on the sub-type, metastasis to the brain predicts an average survival of less than one year and drastically reduces therapeutic options as most targeted therapies cannot cross the blood-brain barrier (BBB). Increased cell surface density of HER3 (or ErbB3) associates with tumor progression, therapeutic resistance and metastasis includi...